NCYT.L Live signals | Maximize Profits with Getagraph.com

Live Chart Being Loaded With Signals

Commentary (18 Apr 2024 @ 11:35):

Stats
Today's Volume	493 354
Average Volume	64 640.00
Market Cap	45.48M
Last Dividend	£0 ( N/A )
Next Dividend	£0 ( N/A )
P/E	-1.790
ATR14	£0.673 (1.05%)

Volume Correlation

Long: 0.02 (neutral)

Short: 0.79 (moderate)

Signal:(38.982) Neutral

Novacyt SA Correlation

10 Most Positive Correlations

10 Most Negative Correlations

Did You Know?

Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).

Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.

Novacyt SA Correlation - Currency/Commodity

0.68
( moderate )

0.32
( neutral )

-0.04
( neutral )

-0.35
( neutral )

-0.03
( neutral )

0.27
( neutral )

Novacyt SA Financials

Annual	2023
Revenue:	£11.56M
Gross Profit:	£11.56M (100.00 %)
EPS:	£0

Q4	2023
Revenue:	£8.30M
Gross Profit:	£8.30M (100.00 %)
EPS:	£0

Q2	2023
Revenue:	£3.27M
Gross Profit:	£496 219 (15.15 %)
EPS:	£-0.120

Q4	2022
Revenue:	£4.65M
Gross Profit:	£678 947 (14.61 %)
EPS:	£-0.250

Financial Reports:

No articles found.

Novacyt SA

Novacyt S.A., together with its subsidiaries, engages in the development, manufacture, contract design, and commercialization of diagnostic products for cancer and infectious diseases in the United Kingdom, rest of Europe, the United States, the Asia Pacific, the Middle East, and Africa. It operates through Primer Design, Lab21 Products, and IT-IS International. The Primer Design segment designs, manufactures, and markets molecular real-time qPCR testing devices and reagents in the areas of infectious diseases. The Lab21 Products segment develops, manufactures, and distributes a range of protein-based infectious disease in-vitro diagnostic device (IVD) products. The IT-IS International segment develops and manufactures PCR devices for the life sciences and food testing industry. It serves hospitals and corporates. The company was incorporated in 2006 and is based in Vélizy-Villacoublay, France.